CBT-008 is a follow-on drug of CBT-006 that can also sequester cholesterol as a molecule. A novel mechanism of action is adopted for treating Meibomian Gland Dysfunction Associated Dry Eye Disease. Applied topically in repeat dosing as eye drops, CBT-008 will dissolve potential cholesterol crystals deposited at the orifice of meibomian glands to improve meibum quality, which further enhances tear film stability.  

CBT-008 has been revealed to be well-tolerated in chronic ocular toxicity studies in animal models. CBT-008 is in Phase II clinical trial. The drug is expected to be safe and more potent than CBT-006.